Novel approaches in anti-angiogenic treatment targeting endothelial F-actin: A new anti-angiogenic strategy?

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 6, 2008, Pages 579-590

  Thoenes, L ^a   Gunther M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Actin; Angiogenesis; Cancer; Cell motility; Cytoskeleton; Migration

Indexed keywords

A 176120; ACTIN RELATED PROTEIN 2-3 COMPLEX; ALENDRONIC ACID; ANGIOSTATIN; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; BLEBBISTATIN; CILENGITIDE; CYCLOPHOSPHAMIDE; DIACETYL OXIME; F ACTIN; FLUOROURACIL; GAMBOGIC ACID; GERANYLGERANYLTRANSFERASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; LIPOCORTIN 2; MYOSIN II; MYOSIN LIGHT CHAIN KINASE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PAMIDRONIC ACID; RECOMBINANT PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; RISEDRONIC ACID; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2; WF 536; WISKOTT ALDRICH SYNDROME PROTEIN; ZOLEDRONIC ACID;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; CANCER THERAPY; CELL MOTILITY; CLINICAL TRIAL; CYTOSKELETON; DRUG TARGETING; GENE THERAPY; HUMAN; NONHUMAN; REVIEW;

ACTINS; ALKYL AND ARYL TRANSFERASES; ANGIOGENESIS INHIBITORS; ENDOTHELIAL CELLS; HUMANS; MODELS, BIOLOGICAL; MYOSIN TYPE II; MYOSIN-LIGHT-CHAIN KINASE; NEOVASCULARIZATION, PATHOLOGIC; RHO-ASSOCIATED KINASES;

EID: 57349180848     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (169)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin (2005) 55(2):74-108.
2. Naumov GN, Akslen LA, Folkman J: Role of angiogenesis in human tumor dormancy: Animal models of the angiogenic switch. Cell Cycle (2006) 5(16):1779-1787. • An excellent review describing sequential events in tumor progression and the role of angiogenesis in tumor growth.
3. Hockel M, Vaupel P: Biological consequences of tumor hypoxia. Semin Oncol (2001) 28(2 Suppl 8):36-41.
4. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG: Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol (2005) 7(2):134-153.
5. Tong Q, Zheng L, Lin L, Li B, Wang D, Huang C, Li D: VEGF is upregulated by hypoxia-induced mitogenic factor via the PI-3K/Akt-NF-κB signaling pathway. Respir Res (2006) 7:37.
6. vβ5 in cultured human endothelial cells. J Cell Biochem (2000) 78(4):674-680.
7. Tong Q, Zheng L, Lin L, Li B, Wang D, Huang C, Matuschak GM, Li D: Participation of the PI-3K/Akt-NF-κB signaling pathways in hypoxia-induced mitogenic factor-stimulated Flk-1 expression in endothelial cells. Respir Res (2006) 7:101.
8. Secomb TW, Hsu R, Dewhirst MW, Klitzman B, Gross JF: Analysis of oxygen transport to tumor tissue by microvascular networks. Int J Radiat Oncol Biol Phys (1993) 25(3):481-489.
9. Lamalice L, Le Boeuf F, Huot J: Endothelial cell migration during angiogenesis. Circ Res (2007) 100(6):782-794. • This review provides a global overview of endothelial cell migration during angiogenesis and insight into mechanisms involved in actin-based cell motility.
10. Wilson L, Panda D, Jordan MA: Modulation of microtubule dynamics by drugs: A paradigm for the actions of cellular regulators. Cell Struct Funct (1999) 24(5):329-335.
11. Etienne-Manneville S: Actin and microtubules in cell motility: Which one is in control? Traffic (2004) 5(7):470-477.
12. van Nieuw Amerongen GP, Koolwijk P, Versteilen A, van Hinsbergh VW: Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Arterioscler Thromb Vasc Biol (2003) 23(2):211-217.
13. Fenteany G, Zhu S: Small-molecule inhibitors of actin dynamics and cell motility. Curr Top Med Chem (2003) 3(6):593-616.
14. Paavilainen VO, Bertling E, Falck S, Lappalainen P: Regulation of cytoskeletal dynamics by actin-monomer-binding proteins. Trends Cell Biol (2004) 14(7):386-394.
15. Urbanik E, Ware BR: Actin filament capping and cleaving activity of cytochalasins B, D, E, and H. Arch Biochem Biophys (1989) 269(1):181-187.
16. Melkonian G, Munoz N, Chung J, Tong C, Marr R, Talbot P: Capillary plexus development in the day five to day six chick chorioallantoic membrane is inhibited by cytochalasin D and suramin. J Exp Zool (2002) 292(3):241-254.
17. Spector I, Shochet NR, Kashman Y, Groweiss A: Latrunculins: Novel marine toxins that disrupt microfilament organization in cultured cells. Science (1983) 219(4584):493-495.
18. Spector I, Shochet NR, Blasberger D, Kashman Y: Latrunculins - novel marine macrolides that disrupt microfilament organization and affect cell growth: I. Comparison with cytochalasin D. Cell Motil Cytoskeleton (1989) 13(3):127-144.
19. Furstner A, Kirk D, Fenster MD, Aissa C, De Souza D, Nevado C, Tuttle T, Thiel W, Muller O: Latrunculin analogues with improved biological profiles by "diverted total synthesis": Preparation, evaluation, and computational analysis. Chemistry (2007) 13(1):135-149.
20. El Sayed KA, Youssef DT, Marchetti D: Bioactive natural and semisynthetic latrunculins. J Nat Prod (2006) 69(2):219-223.
21. Saito S, Watabe S, Ozaki H, Kigoshi H, Yamada K, Fusetani N, Karaki H: Novel actin depolymerizing macrolide aplyronine A. J Biochem (1996) 120(3):552-555.
22. Kuroda T, Suenaga K, Sakakura A, Handa T, Okamoto K, Kigoshi H: Study of the interaction between actin and antitumor substance aplyronine A with a novel fluorescent photoaffinity probe. Bioconjug Chem (2006) 17(2):524-529.
23. Hirata K, Muraoka S, Suenaga K, Kuroda T, Kato K, Tanaka H, Yamamoto M, Takata M, Yamada K, Kigoshi H: Structure basis for antitumor effect of aplyronine A. J Mol Biol (2006) 356(4):945-954.
24. Allingham JS, Zampella A, D'Auria MV, Rayment I: Structures of microfilament destabilizing toxins bound to actin provide insight into toxin design and activity. Proc Natl Acad Sci USA (2005) 102(41):14527-14532.
25. Youssef DT, Mooberry SL: Hurghadolide A and swinholide I, potent actin-microfilament disrupters from the Red Sea sponge Theonella swinhoei. J Nat Prod (2006) 69(1):154-157.
26. Ares IR, Louzao MC, Espina B, Vieytes MR, Miles CO, Yasumoto T, Botana LM: Lactone ring of pectenotoxins: A key factor for their activity on cytoskeletal dynamics. Cell Physiol Biochem (2007) 19(5-6):283-292.
27. Allingham JS, Miles CO, Rayment I: A structural basis for regulation of actin polymerization by pectenotoxins. J Mol Biol (2007) 371(4):959-970.
28. Cooper JA: Effects of cytochalasin and phalloidin on actin. J Cell Biol (1987) 105(4):1473-1478.
29. Wulf E, Deboben A, Bautz FA, Faulstich H, Wieland T: Fluorescent phallotoxin, a tool for the visualization of cellular actin. Proc Natl Acad Sci USA (1979) 76(9):4498-4502.
30. Loranger A, Tuchweber B, Gicquaud C, St Pierre S, Cote MG: Toxicity of peptides of Amanita virosa mushrooms in mice. Fundam Appl Toxicol (1985) 5(6 Pt 1):1144-1152.
31. Bubb MR, Spector I, Beyer BB, Fosen KM: Effects of jasplakinolide on the kinetics of actin polymerization. An explanation for certain in vivo observations. J Biol Chem (2000) 275(7):5163- 5170.
32. Bai R, Verdier-Pinard P, Gangwar S, Stessman CC, McClure KJ, Sausville EA, Pettit GR, Bates RB, Hamel E: Dolastatin 11, a marine depsipeptide, arrests cells at cytokinesis and induces hyperpolymerization of purified actin. Mol Pharmacol (2001) 59(3):462-469.
33. Bai R, Covell DG, Liu C, Ghosh AK, Hamel E: (-)-Doliculide, a new macrocyclic depsipeptide enhancer of actin assembly. J Biol Chem (2002) 277(35):32165-32171.
34. Oguchi K, Tsuda M, Iwamoto R, Okamoto Y, Endo T, Kobayashi J, Ozawa T, Masuda A: Amphidinolides B6 and B7, cytotoxic macrolides from a symbiotic dinoflagellate Amphidinium species. J Nat Prod (2007) 70(10):1676-1679.
35. Usui T, Kazami S, Dohmae N, Mashimo Y, Kondo H, Tsuda M, Terasaki AG, Ohashi K, Kobayashi J, Osada H: Amphidinolide H, a potent cytotoxic macrolide, covalently binds on actin subdomain 4 and stabilizes actin filament. Chem Biol (2004) 11(9):1269-1277.
36. Terracciano S, Bruno I, D'Amico E, Bifulco G, Zampella A, Sepe V, Smith CD, Riccio R: Synthetic and pharmacological studies on new simplified analogues of the potent actin-targeting jaspamide. Bioorg Med Chem (2008) 16(13): 6580-6588.
37. de Leeuw M, Roiz L, Smirnoff P, Schwartz B, Shoseyov O, Almog O: Binding assay and preliminary X-ray crystallographic analysis of ACTIBIND, a protein with anticarcinogenic and antiangiogenic activities. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 63(8):716-719.
38. Roiz L, Smirnoff P, Bar-Eli M, Schwartz B, Shoseyov O: ACTIBIND, an actin-binding fungal T2-RNase with antiangiogenic and anticarcinogenic characteristics. Cancer (2006) 106(10):2295-2308. •• This study showed that actin-binding glycoproteins, a novel class of actin interacting agents, exert potent anti-angiogenic activity with comparatively low side effects.
39. Schwartz B, Shoseyov O, Melnikova VO, McCarty M, Leslie M, Roiz L, Smirnoff P, Hu GF, Lev D, Bar-Eli M: ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis. Cancer Res (2007) 67(11):5258-5266. •• ACTIBIND exhibited strong anti-angiogenic activity in an aggressive melanoma xenograft model and led to inhibition of tumor progression.
40. Smirnoff P, Roiz L, Angelkovitch B, Schwartz B, Shoseyov O: A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics: Expression, purification, and characterization. Cancer (2006) 107(12):2760-2769. •• RNASET2, similar to ACTIBIND, strongly inhibited tumor angiogenesis in vitro and in vivo.
41. Fujiwara H, Saito SY, Hitotsuyanagi Y, Takeya K, Ohizumi Y: RA-VII, a cyclic depsipeptide, changes the conformational structure of actin to cause G2 arrest by the inhibition of cytokinesis. Cancer Lett (2004) 209(2):223-229.
42. Koizumi T, Abe M, Yamakuni T, Ohizumi Y, Hitotsuyanagi Y, Takeya K, Sato Y: Metronomic scheduling of a cyclic hexapeptide Ra-VII for anti-angiogenesis, tumor vessel maturation and anti-tumor activity. Cancer Sci (2006) 97(7):665-674.
43. Perrins RD, Cecere G, Paterson I, Marriott G: Synthetic mimetics of actin-binding macrolides: Rational design of actin-targeted drugs. Chem Biol (2008) 15(3):287-294.
44. Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS: From combinatorial chemistry to cancer-targeting peptides. Mol Pharm (2007) 4(5):631-651.
45. Ruoslahti E, Rajotte D: An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol (2000) 18:813-827.
46. vβ3 integrin via binding to the extracellular domain of KDR. Mol Pharmacol (2007) 72(3):545-552.
47. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T: Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys (2008) 71(5):1372-1380.
48. Bokstein F, Shpigel S, Blumenthal DT: Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer (2008) 112(10):2267-2273.
49. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 24(1):16-24.
50. Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM: Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol (2008) 179(1):81-86.
51. Blumenschein G Jr: Sorafenib in lung cancer: Clinical developments and future directions. J Thorac Oncol (2008) 3(6 Suppl 2):S124-S127.
52. Reddy GK, Bukowski RM: Sorafenib: Recent update on activity as a single agent and in combination with interferon-α2 in patients with advanced-stage renal cell carcinoma. Clin Genitourin Cancer (2006) 4(4):246-248.
53. Smith JW: Cilengitide Merck. Curr Opin Investig Drugs (2003) 4(6):741-745.
54. MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE: Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol (2008) 26(6):919-924.
55. Dixelius J, Olsson AK, Thulin A, Lee C, Johansson I, Claesson-Welsh L: Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein. Cancer Res (2006) 66(4):2089- 2097.
56. Mermall V, Post PL, Mooseker MS: Unconventional myosins in cell movement, membrane traffic, and signal transduction. Science (1998) 279(5350):527-533.
57. Somlyo AV, Phelps C, Dipierro C, Eto M, Read P, Barrett M, Gibson JJ, Burnitz MC, Myers C, Somlyo AP: Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB J (2003) 17(2):223-234.
58. Higuchi H, Takemori S: Butanedione monoxime suppresses contraction and ATPase activity of rabbit skeletal muscle. J Biochem (1989) 105(4):638-643.
59. Cheung A, Dantzig JA, Hollingworth S, Baylor SM, Goldman YE, Mitchison TJ, Straight AF: A small-molecule inhibitor of skeletal muscle myosin II. Nat Cell Biol (2002) 4(1):83-88.
60. Straight AF, Cheung A, Limouze J, Chen I, Westwood NJ, Sellers JR, Mitchison TJ: Dissecting temporal and spatial control of cytokinesis with a myosin II inhibitor. Science (2003) 299(5613):1743-1747.
61. Kolega J: The role of myosin II motor activity in distributing myosin asymmetrically and coupling protrusive activity to cell translocation. Mol Biol Cell (2006) 17(10):4435-4445.
62. Ohlmann P, Tesse A, Loichot C, Ralay RH, Roul G, Philippe C, Watterson DM, Haiech J, Andriantsitohaina R: Deletion of MLCK210 induces subtle changes in vascular reactivity but does not affect cardiac function. Am J Physiol Heart Circ Physiol (2005) 289(6):H2342-H2349.
63. Behanna HA, Watterson DM, Ranaivo HR: Development of a novel bioavailable inhibitor of the calmodulin-regulated protein kinase MLCK: A lead compound that attenuates vascular leak. Biochim Biophys Acta (2006) 1763(11):1266-1274.
64. Xia D, Stull JT, Kamm KE: Myosin phosphatase targeting subunit 1 affects cell migration by regulating myosin phosphorylation and actin assembly. Exp Cell Res (2005) 304(2):506-517.
65. Goley ED, Welch MD: The ARP2/3 complex: An actin nucleator comes of age. Nat Rev Mol Cell Biol (2006) 7(10):713-726.
66. Miki H, Takenawa T: Regulation of actin dynamics by WASP family proteins. J Biochem (2003) 134(3):309-313.
67. Calhoun CC, Lu YC, Song J, Chiu R: Knockdown endogenous CypA with siRNA in U2OS cells results in disruption of F-actin structure and alters tumor phenotype. Mol Cell Biochem (2008):DOI: 10.1007/s11010-008-9896-0.
68. Peterson JR, Lokey RS, Mitchison TJ, Kirschner MW: A chemical inhibitor of N-WASP reveals a new mechanism for targeting protein interactions. Proc Natl Acad Sci USA (2001) 98(19):10624- 10629.
69. Peterson JR, Bickford LC, Morgan D, Kim AS, Ouerfelli O, Kirschner MW, Rosen MK: Chemical inhibition of N-WASP by stabilization of a native autoinhibited conformation. Nat Struct Mol Biol (2004) 11(8):747-755.
70. Ivanov AI, Hunt D, Utech M, Nusrat A, Parkos CA: Differential roles for actin polymerization and a myosin II motor in assembly of the epithelial apical junctional complex. Mol Biol Cell (2005) 16(6):2636- 2650.
71. Guerriero CJ, Weisz OA: N-WASP inhibitor wiskostatin nonselectively perturbs membrane transport by decreasing cellular ATP levels. Am J Physiol Cell Physiol (2007) 292(4):C1562-C1566.
72. Jaffe AB, Hall A: Rho GTPases: Biochemistry and biology. Annu Rev Cell Dev Biol (2005) 21:247-269.
73. Rak J, Yu JL, Kerbel RS, Coomber BL: What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res (2002) 62(7):1931-1934.
74. Bryan BA, D'Amore PA: What tangled webs they weave: Rho-GTPase control of angiogenesis. Cell Mol Life Sci (2007) 64(16):2053-2065.
75. Fritz G, Kaina B: Rho GTPases: Promising cellular targets for novel anticancer drugs. Curr Cancer Drug Targets (2006) 6(1):1-14.
76. El Oualid F, Cohen LH, van der Marel GA, Overhand M: Inhibitors of protein: Geranylgeranyl transferases. Curr Med Chem (2006) 13(20):2385-2427.
77. Lee S, Park S, Oh JW, Yang C: Natural inhibitors for protein prenyltransferase. Planta Med (1998) 64(4):303-308.
78. Golovchenko I, Yang CH, Goalstone ML, Draznin B: Garlic extract methylallyl thiosulfinate blocks insulin potentiation of platelet-derived growth factor-stimulated migration of vascular smooth muscle cells. Metabolism (2003) 52(2):254-259.
79. Lee HJ, Lee JH, Hwang BY, Kim HS, Lee JJ: Anti-angiogenic activities of gliotoxin and its methylthioderivative, fungal metabolites. Arch Pharm Res (2001) 24(5):397-401.
80. Choi HS, Shim JS, Kim JA, Kang SW, Kwon HJ: Discovery of gliotoxin as a new small molecule targeting thioredoxin redox system. Biochem Biophys Res Commun (2007) 359(3):523-528.
81. Tahir SK, Gu WZ, Zhang HC, Leal J, Lee JY, Kovar P, Saeed B, Cherian SP, Devine E, Cohen J, Warner R et al: Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue. Eur J Cancer (2000) 36(9):1161-1170.
82. Bocci G, Danesi R, Del Tacca M, Kerbel RS: Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor. Eur J Pharmacol (2003) 477(1):17-21.
83. Ho PY, Zhong WB, Ho YS, Lee WS: Terbinafine inhibits endothelial cell migration through suppression of the Rho-mediated pathway. Mol Cancer Ther (2006) 5(12):3130-3138.
84. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res (2002) 91(2):143-150.
85. Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi-Khorassani T, Vannier JP, Soria J, Soria C: Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: Contribution to its anti-angiogenic effect. FEBS Lett (2001) 495(3):159-166.
86. Hindler K, Cleeland CS, Rivera E, Collard CD: The role of statins in cancer therapy. Oncologist (2006) 11(3):306-315.
87. Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, Moore MJ, Chin S, Irish J, LaFramboise S, Oza AM: A phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer (2005) 41(4):523-530.
88. Vitols S, Angelin B, Juliusson G: Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans - in vitro and in vivo studies. Lipids (1997) 32(3):255-262.
89. Lopez-Aguilar E, Sepulveda-Vildosola AC, Rivera-Marquez H, Cerecedo-Diaz F, Valdez-Sanchez M, Villasis-Keever MA: Security and maximal tolerated doses of fluvastatin in pediatric cancer patients. Arch Med Res (1999) 30(2):128-131.
90. Minden MD, Dimitroulakos J, Nohynek D, Penn LZ: Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma (2001) 40(5-6):659-662.
91. Lersch C, Schmelz R, Erdmann J, Hollweck R, Schulte-Frohlinde E, Eckel F, Nader M, Schusdziarra V: Treatment of HCC with pravastatin, octreotide, or gemcitabine - a critical evaluation. Hepatogastroenterology (2004) 51(58):1099-1103.
92. Hashimoto K, Morishige K, Sawada K, Tahara M, Shimizu S, Ogata S, Sakata M, Tasaka K, Kimura T: Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem Biophys Res Commun (2007) 354(2):478-484. • This study on anti-angiogenic activity of alendronate provided great insight into mechanisms and correlations between VEGF-driven endothelial activation and butylphthalide interaction.
93. Tuomela JM, Valta MP, Vaananen K, Harkonen PL: Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice. BMC Cancer (2008) 8:81.
94. Roelofs AJ, Thompson K, Gordon S, Rogers MJ: Molecular mechanisms of action of bisphosphonates: Current status. Clin Cancer Res (2006) 12(20 Pt 2):6222s-6230s.
95. Koizumi M, Nakaseko C, Ohwada C, Takeuchi M, Ozawa S, Shimizu N, Cho R, Nishimura M, Saito Y: Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells. Eur J Haematol (2007) 79(5):382-391.
96. Denoyelle C, Hong L, Vannier JP, Soria J, Soria C: New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer (2003) 88(10):1631-1640.
97. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 296(2):235-242.
98. Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W: Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem (2006) 1(2):267-273.
99. Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RG, Oppermann U: The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA (2006) 103(20):7829-7834.
100. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther (2002) 302(3):1055-1061.
101. Scavelli C, Di Pietro G, Cirulli T, Coluccia M, Boccarelli A, Giannini T, Mangialardi G, Bertieri R, Coluccia AM, Ribatti D, Dammacco F, Vacca A: Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther (2007) 6(12 Pt 1):3256-3262.
102. Backman U, Svensson A, Christofferson RH, Azarbayjani F: The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res (2008) 28(3A):1551-1557.
103. Soltau J, Zirrgiebel U, Esser N, Schachtele C, Totzke F, Unger C, Merfort I, Drevs J: Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res (2008) 28(2A):933-941.
104. Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, Salesi N, Giannarelli D, Alimonti A, Di Cocco B, D'Agosto G et al: Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology (2005) 69(1):35-43.
105. Winter MC, Holen I, Coleman RE: Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev (2008) 34(5):453-475.
106. Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A, Grilli C, Virzi V, Gasparro S, Rocci L, Tonini G: Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res (2005) 25(3):144-151.
107. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G: Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res (2002) 8(5):1080-1084.
108. Ciepluch H, Baran W, Hellmann A: Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. Med Sci Monit (2002) 8(4):PI31-PI36.
109. Leung T, Manser E, Tan L, Lim L: A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem (1995) 270(49):29051-29054.
110. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K: Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J (1996) 15(9):2208-2216.
111. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kakizuka A, Morii N, Narumiya S: The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J (1996) 15(8):1885-1893.
112. Leung T, Chen XQ, Manser E, Lim L: The p160 RhoA-binding kinase ROK a is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol (1996) 16(10):5313-5327.
113. Fukata Y, Amano M, Kaibuchi K: Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci (2001) 22(1):32-39.
114. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP: Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun (2000) 269(3):652-659.
115. Tamura M, Nakao H, Yoshizaki H, Shiratsuchi M, Shigyo H, Yamada H, Ozawa T, Totsuka J, Hidaka H: Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta (2005) 1754(1-2):245-252.
116. Nakajima M, Hayashi K, Egi Y, Katayama K, Amano Y, Uehata M, Ohtsuki M, Fujii A, Oshita K, Kataoka H, Chiba K et al: Effect of WF-536, a novel ROCK inhibitor, against metastasis of B16 melanoma. Cancer Chemother Pharmacol (2003) 52(4):319-324.
117. Nakajima M, Hayashi K, Katayama K, Amano Y, Egi Y, Uehata M, Goto N, Kondo T: WF-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions. Eur J Pharmacol (2003) 459(2-3):113- 120.
118. Yin L, Morishige K, Takahashi T, Hashimoto K, Ogata S, Tsutsumi S, Takata K, Ohta T, Kawagoe J, Takahashi K, Kurachi H: Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther (2007) 6(5):1517-1525.
119. Hata Y, Miura M, Nakao S, Kawahara S, Kita T, Ishibashi T: Antiangiogenic properties of fasudil, a potent Rho-kinase inhibitor. Jpn J Ophthalmol (2008) 52(1):16-23.
120. Waisman DM: Annexin II tetramer: Structure and function. Mol Cell Biochem (1995) 149-150:301-322.
121. Hayes MJ, Shao D, Bailly M, Moss SE: Regulation of actin dynamics by annexin 2. EMBO J (2006) 25(9):1816-1826.
122. Heyraud S, Jaquinod M, Durmort C, Dambroise E, Concord E, Schaal JP, Huber P, Gulino-Debrac D: Contribution of annexin 2 to the architecture of mature endothelial adherens junctions. Mol Cell Biol (2008) 28(5):1657-1668.
123. Falsey RR, Marron MT, Gunaherath GM, Shirahatti N, Mahadevan D, Gunatilaka AA, Whitesell L: Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat Chem Biol (2006) 2(1):33-38.
124. Bargagna-Mohan P, Hamza A, Kim YE, Khuan Abby Ho Y, Mor-Vaknin N, Wendschlag N, Liu J, Evans RM, Markovitz DM, Zhan CG, Kim KB, Mohan R: The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol (2007) 14(6):623-634.
125. Devi PU: Withania somnifera Dunal (Ashwagandha): Potential plant source of a promising drug for cancer chemotherapy and radiosensitization. Indian J Exp Biol (1996) 34(10):927-932.
126. Mohan R, Hammers HJ, Bargagna-Mohan P, Zhan XH, Herbstritt CJ, Ruiz A, Zhang L, Hanson AD, Conner BP, Rougas J, Pribluda VS: Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis (2004) 7(2):115-122.
127. O'Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med (1996) 2(6):689-692.
128. Ji WR, Castellino FJ, Chang Y, Deford ME, Gray H, Villarreal X, Kondri ME, Marti DN, Llinas M, Schaller J, Kramer RA, Trail PA: Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J (1998) 12(15):1731-1738.
129. Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B, O'Reilly M, Folkman J: Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci USA (1998) 95(10):5579-5583.
130. Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, Borlat F, Sim BK, Wu Z, Grau GE, Shing Y, Soff GA et al: Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood (1998) 92(12):4730-4741.
131. Dudani AK, Ben-Tchavtchavadze M, Porter S, Tackaberry E: Angiostatin and plasminogen share binding to endothelial cell surface actin. Biochem Cell Biol (2005) 83(1):28-35.
132. Kurup A, Lin CW, Murry DJ, Dobrolecki L, Estes D, Yiannoutsos CT, Mariano L, Sidor C, Hickey R, Hanna N: Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: A phase II study from Indiana University. Ann Oncol (2006) 17(1):97-103.
133. Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P, Soria C, Perricaudet M, Yeh P, Lu H: Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA (1998) 95(11):6367-6372.
134. Kato K, Miyake K, Igarashi T, Yoshino S, Shimada T: Human immunodeficiency virus vector-mediated intra-articular expression of angiostatin inhibits progression of collagen-induced arthritis in mice. Rheumatol Int (2005) 25(7):522-529.
135. Chen QR, Kumar D, Stass SA, Mixson AJ: Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res (1999) 59(14):3308-3312.
136. Andrawiss M, Maron A, Beltran W, Opolon P, Connault E, Griscelli F, Yeh P, Perricaudet M, Devauchelle P: Adenovirus-mediated gene transfer in canine eyes: A preclinical study for gene therapy of human uveal melanoma. J Gene Med (2001) 3(3):228-239.
137. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88(2):277-285.
138. Folkman J: Antiangiogenesis in cancer therapy - Endostatin and its mechanisms of action. Exp Cell Res (2006) 312(5):594-607.
139. Wickstrom SA, Alitalo K, Keski-Oja J: Endostatin associates with integrin α5β1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res (2002) 62(19):5580-5589.
140. Dixelius J, Cross M, Matsumoto T, Sasaki T, Timpl R, Claesson-Welsh L: Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res (2002) 62(7):1944-1947.
141. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A et al: Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol (2006) 24(22):3555-3561.
142. Moschos SJ, Odoux C, Land SR, Agarwala S, Friedland D, Volker KM, Sidor C, Wong M, Kirkwood JM: Endostatin plus interferon-α2b therapy for metastatic melanoma: A novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res (2007) 17(3):193-200.
143. Lin X, Huang H, Li S, Li H, Li Y, Cao Y, Zhang D, Xia Y, Guo Y, Huang W, Jiang W: A phase I clinical trial of an adenovirusmediated endostatin gene (E10A) in patients with solid tumors. Cancer Biol Ther (2007) 6(5):648-653.
144. Li HL, Li S, Shao JY, Lin XB, Cao Y, Jiang WQ, Liu RY, Zhao P, Zhu XF, Zeng MS, Guan ZZ, Huang W: Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors. Gene Ther (2008) 15(4):247-256.
145. Keezer SM, Ivie SE, Krutzsch HC, Tandle A, Libutti SK, Roberts DD: Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. Cancer Res (2003) 63(19):6405-6412.
146. Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA, Humerickhouse RA, Qian J, Gordon GB, Figlin R: Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res (2007) 13(22 Pt 1):6689-6695.
147. Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA et al: A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol (2007) 30(3):303-309.
148. Bix G, Fu J, Gonzalez EM, Macro L, Barker A, Campbell S, Zutter MM, Santoro SA, Kim JK, Hook M, Reed CC, Iozzo RV: Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through α2β1 integrin. J Cell Biol (2004) 166(1):97-109. • This study provided a detailed insight into the mechanism of action of endorepellin.
149. Woodall BP, Nystrom A, Iozzo RA, Eble JA, Niland S, Krieg T, Eckes B, Pozzi A, Iozzo RV: Integrin α2β1 is the required receptor for endorepellin angiostatic activity. J Biol Chem (2008) 283(4):2335-2343.
150. Bix G, Castello R, Burrows M, Zoeller JJ, Weech M, Iozzo RA, Cardi C, Thakur ML, Barker CA, Camphausen K, Iozzo RV: Endorepellin in vivo: Targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst (2006) 98(22):1634-1646. •• Endorepellin localized to the tumor vasculature and exerted a strong anti-angiogenic and antitumoral activity in vivo.
151. Akahane T, Akahane M, Shah A, Connor CM, Thorgeirsson UP: TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp Cell Res (2004) 301(2):158- 167.
152. Guruvayoorappan C, Kuttan G: Inhibition of tumor specific angiogenesis by amentoflavone. Biochemistry (Mosc) (2008) 73(2):209-218.
153. Lee C, Dixelius J, Thulin A, Kawamura H, Claesson-Welsh L, Olsson AK: Signal transduction in endothelial cells by the angiogenesis inhibitor histidine-rich glycoprotein targets focal adhesions. Exp Cell Res (2006) 312(13):2547-2556.
154. Dixelius J, Olsson AK, Thulin A, Lee C, Johansson I, Claesson-Welsh L: Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein. Cancer Res (2006) 66(4):2089- 2097.
155. Shen WG, Xue QY, Wu YD, Hu BS, Zhu J, Zhang Y, Su Q: Melanoma- associated antigen family protein-D1 regulation of tumor cell migration, adhesion to endothelium, and actin structures reorganization in response to hypoxic stress. Cell Commun Adhes (2007) 14(1):21-31.
156. Shen WG, Xue QY, Zhu J, Hu BS, Zhang Y, Wu YD, Su Q: Inhibition of adenovirus-mediated human MAGE-D1 on angiogenesis in vitro and in vivo. Mol Cell Biochem (2007) 300(1-2):89- 99.
157. Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, Kerbel RS: A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res (2004) 64(11):3994-4000.
158. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res (2000) 60(7):1878-1886.
159. Gille J, Spieth K, Kaufmann R: Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer. J Dtsch Dermatol Ges (2005) 3(1):26-32.
160. Mohay J, McLaughlin BJ: Corneal endothelial wound repair in normal and mitotically inhibited cultures. Graefes Arch Clin Exp Ophthalmol (1995) 233(11):727-736.
161. Gordon SR, Climie M, Hitt AL: 5-Fluorouracil interferes with actin organization, stress fiber formation and cell migration in corneal endothelial cells during wound repair along the natural basement membrane. Cell Motil Cytoskeleton (2005) 62(4):244-258.
162. Ooyama A, Oka T, Zhao HY, Yamamoto M, Akiyama S, Fukushima M: Anti-angiogenic effect of 5-fluorouracil-based drugs against human colon cancer xenografts. Cancer Lett (2008) 267(1):26-36.
163. Zhao HY, Ooyama A, Yamamoto M, Ikeda R, Haraguchi M, Tabata S, Furukawa T, Che XF, Zhang S, Oka T, Fukushima M et al: Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil. Cancer Res (2008) 68(17):7035-7041. •• Induction of endogenous TSP-1 levels in metronomic regimes may be the mechanism of anti-angiogenic activity utilized by several conventional anticancer drugs.
164. Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, Viacava P, Naccarato AG, Kerbel RS, Danesi R, Del Tacca M, Allegrini G: Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer (2008) 98(10):1619-1629.
165. Dalle-Donne I, Carini M, Vistoli G, Gamberoni L, Giustarini D, Colombo R, Maffei Facino R, Rossi R, Milzani A, Aldini G: Actin Cys374 as a nucleophilic target of α,β-unsaturated aldehydes. Free Radic Biol Med (2007) 42(5):583-598.
166. Gunther M, Wagner E, Ogris M: Acrolein: Unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy? J Cell Mol Med (2008): doi: 10.1111/j.1582-4934.2008.00255. x.
167. Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB, Liu M: Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res (2008) 68(6):1843-1850.
168. Koizumi T, Abe M, Yamakuni T, Ohizumi Y, Hitotsuyanagi Y, Takeya K, Sato Y: Metronomic scheduling of a cyclic hexapeptide Ra-VII for anti-angiogenesis, tumor vessel maturation and anti-tumor activity. Cancer Sci (2006) 97(7):665-674.
169. The Children's Medical Center Corp (Udagawa T, D'Amato RJ, Shah JH): Cytochalasin and isoindolinone derivates as inhibitors of angiogenesis. US-05994388 (1999).